Company Profile
Equillium, Inc. Stock Price, News & Analysis
- Ticker:
- EQ
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
2.12 USD (-3.20%)
Close
Last updated: August 6, 2026
176M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, EQ closed down 3.20% at $2.12. No new same-company headline was identified in the current news window.
Company overview
Immunobiology Company
Equillium develops therapies for severe autoimmune and inflammatory disorders using mechanisms intended to restore immune balance.
EQ504
EQ504 is a selective aryl hydrocarbon receptor modulator with a multimodal, non-immunosuppressive mechanism designed to support barrier function and regulate tissue inflammation.
Local Delivery Strategy
Potential formulations include targeted gastrointestinal delivery for ulcerative colitis and inhaled delivery for inflammatory lung diseases.
Future catalysts
A Phase 1 proof-of-mechanism study of EQ504 is expected to begin in mid-2026.
Initial study data are expected approximately six months after initiation.
Recent news
- 01
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Source: Equillium, Inc.
- 02
Equillium to Participate in the 2026 Jefferies Global Healthcare Conference
Source: Equillium, Inc.
- 03
- 04
Equillium Reports First Quarter 2026 Financial Results and Corporate Highlights
Source: Equillium, Inc.
- 05
Equillium to Participate in Oppenheimer’s 2026 Innovation on the Island Event
Source: Equillium, Inc.
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Equillium, Inc. (EQ)?
Equillium, Inc. (EQ) most recently closed at 2.12 USD, a -3.20% move versus the previous session.
What is the market cap of Equillium, Inc. (EQ)?
Equillium, Inc. currently has a market capitalization of 176M USD on BioPharmSignal.
What does Equillium, Inc. do?
Immunobiology Company Equillium develops therapies for severe autoimmune and inflammatory disorders using mechanisms intended to restore immune balance. EQ504 EQ504 is a selective aryl hydrocarbon receptor modulator with a multimodal, non-immunosuppressive mechanism designed to support barrier function and regulate tissue inflammation. Local Delivery...
On which exchange is EQ stock listed?
Equillium, Inc. (EQ) is associated with NASDAQ, United States, Biopharma.
What is Immunobiology?
Immunobiology Company Equillium develops therapies for severe autoimmune and inflammatory disorders using mechanisms intended to restore immune balance.
Which conditions is Equillium, Inc. targeting with Immunobiology?
Equillium, Inc. is associated with inflammatory disease based on its company overview and current catalyst commentary.
How does Equillium, Inc. describe recent progress with Immunobiology?
A Phase 1 proof-of-mechanism study of EQ504 is expected to begin in mid-2026. Initial study data are expected approximately six months after initiation.
What is Equillium?
Immunobiology Company Equillium develops therapies for severe autoimmune and inflammatory disorders using mechanisms intended to restore immune balance.